Olympus Corporation

Global Vessel Sealing Devices Market Report to 2030 - Featuring Johnson & Johnson, Medtronic, B. Braun Melsungen and Aktiengesellschaft Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 26, 2023

Vessel Sealing Devices are used in non-invasive surgical procedure for cutting, coagulating, separate and seal the blood vessels.

Key Points: 
  • Vessel Sealing Devices are used in non-invasive surgical procedure for cutting, coagulating, separate and seal the blood vessels.
  • The vessel sealing devices have active electrodes that circuits the AC current aiming the target tissue.
  • Various factors such as reliability, efficiency is considered while choosing the appropriate vessel sealing devices.
  • Global Vessel Sealing Devices Market: Segmentation Analysis
    The Global Vessel Sealing Devices Market is segmented based on Application, Product Type, Energy Type, End-User, and Geography.

Endoscopy Devices Applications and Global Markets Report 2023: A $75.9 Billion Market by 2027 - Market is Positioned for Significant Growth in the Next Five Years

Retrieved on: 
Monday, February 20, 2023

DUBLIN, Feb. 20, 2023 /PRNewswire/ -- The "Endoscopy Devices: Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 20, 2023 /PRNewswire/ -- The "Endoscopy Devices: Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The global endoscopy device is projected to be valued at $75.9 billion by 2027 from $51.7 billion in 2022, growing at a CAGR of 8%
    This research report provides a comprehensive analysis of endoscopy devices.
  • Endoscopy is a significant component of the global market for medical devices.
  • The endoscopy market is positioned for significant growth in the next five years, due in part to innovations in technology and new applications of those technologies.

Olympus Wins 2022 GOOD DESIGN Award

Retrieved on: 
Wednesday, January 25, 2023

WESTBOROUGH, Mass., Jan. 25, 2023 /PRNewswire/ -- The Olympus POWERSEAL™  5mm Curved Jaw Sealer/Divider, Double-Action won the 2022 GOOD DESIGN® Award within the Medical Category. Olympus is a global technology leader in designing and delivering innovative solutions for medical and surgical procedures. 

Key Points: 
  • WESTBOROUGH, Mass., Jan. 25, 2023 /PRNewswire/ -- The Olympus POWERSEAL™ 5mm Curved Jaw Sealer/Divider, Double-Action won the 2022 GOOD DESIGN® Award within the Medical Category.
  • Approximately 4,000 shortlisted entries were judged by independent and international jurors with the awards given to the designs with the highest design quality, innovation degree, and superior design.
  • "We are thrilled to see that the thoughtful design of the POWERSEAL has been recognized with a Good Design Award," said Phil Roy, Global Vice President for Surgical Devices at Olympus Corporation.
  • GOOD DESIGN is the first, oldest and longest running design prize in the world that honors all design achievements in all its disciplines.

Global Biophotonics Market Report 2022 to 2027: Industry Trends, Share, Size, Growth, Opportunities and Forecasts

Retrieved on: 
Tuesday, January 10, 2023

DUBLIN, Jan. 10, 2023 /PRNewswire/ -- The "Biophotonics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 10, 2023 /PRNewswire/ -- The "Biophotonics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global biophotonics market size reached US$ 44.8 Billion in 2021.
  • What has been the impact of COVID-19 on the global biophotonics market?
  • What is the structure of the global biophotonics market and who are the key players?

Xenia Venture Capital Ltd. Is announcing iTind Procedure for Treatment of BPH, Awarded New Code Payment Rate for the Procedure in the US

Retrieved on: 
Tuesday, December 27, 2022

The proposed rule was finalized and announced on November 1, 2022, and rates will be effective January 1, 2023.

Key Points: 
  • The proposed rule was finalized and announced on November 1, 2022, and rates will be effective January 1, 2023.
  • Xenia Venture Capital is an investment company engaged in investing mainly in life science companies in Israel.
  • Xenia also holds 50% of VLX , a technological incubator operating under the Israel Innovation Authority (IIA) incubator program.
  • In addition to financing, Xenia provides its companies with top-notch mentoring, business and strategic counseling, fundraising assistance, and exit planning.

Sinus Dilation Devices Market Report 2022: A $3.8 Billion Global Market by 2027 - Focus on Balloon Dilation Devices, Endoscopes, and Handheld Rhinoscope & Sinoscope - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

The "Sinus Dilation Devices Market by Product (Balloon Dilation Devices, Endoscope (Rhinoscope, Sinoscope), Handheld), Procedure (Standalone, Hybrid), Patient Type (Adult, Pediatric) & Patient Care Setting (Hospitals & ASC, ENT Office) - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sinus Dilation Devices Market by Product (Balloon Dilation Devices, Endoscope (Rhinoscope, Sinoscope), Handheld), Procedure (Standalone, Hybrid), Patient Type (Adult, Pediatric) & Patient Care Setting (Hospitals & ASC, ENT Office) - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • Based on the product, the sinus dilation devices market is classified into Balloon sinus dilation devices, Endoscopes (Sinuscopes, Rhinoscopes), Sinus stents/implants, and Handheld instruments.
  • The growth of this market is majorly driven by the factors such as Advantages of balloon dilation procedures compared to traditional endoscopic sinus surgeries and Elevated regularity in chronic sinusitis.
  • In this report, the sinus dilation devices market is branched into four significant regional segments such as, North America, Europe, Asia Pacific, and the Rest of the World (RoW).

Olympus Announces Support for CMS Rule Change to Eliminate Cost Sharing for Preventive Colorectal Cancer Screenings

Retrieved on: 
Monday, November 14, 2022

CENTER VALLEY, Pa., Nov. 14, 2022 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, today applauded the decision by the Centers for Medicare and Medicaid Services (CMS) to eliminate cost sharing for Medicare beneficiaries who have a colonoscopy in follow-up to a positive at-home colorectal cancer test. Prior to this policy change by CMS, patients whose at-home screen resulted in concerning results were faced with co-pay costs associated with follow-up colonoscopy; these costs are now eliminated for the covered patient. Olympus also supports the decision for Medicare to cover colonoscopies beginning at age 45, which is in line with the new age recommendation from the United States Preventive Services Task Force (USPSTF).1

Key Points: 
  • That's why it's so important to support colon cancer screening and detection by eliminating cost sharing, such as co-pays, when an at-home test reveals the need for a follow-up colonoscopy."
  • CMS is expanding the regulatory definition of colorectal cancer screening tests to include a complete colorectal cancer screening in which a follow-on screening colonoscopy after a Medicare covered non-invasive stool-based colorectal cancer screening test returns a positive result.
  • The USPSTF last year lowered the recommended screening age for those at average risk for colorectal cancer from 50 to 45.
  • The CMS rule change brings Medicare coverage in line with USPSTF recommendations and makes coverage consistent with Medicaid and most private coverage.

Medicare Issues Final Rule that Increases Payment Rates for iTind Procedure Performed in Outpatient Settings

Retrieved on: 
Thursday, November 3, 2022

CENTER VALLEY, Pa., Nov. 3, 2022 /PRNewswire/ -- Olympus Corporation, a global medical technology company committed to making people's lives healthier, safer, and more fulfilling, announced that the Centers for Medicare and Medicaid Services (CMS) will increase payment rates for the iTind™ procedure performed in the hospital-based outpatient department (HOPD) and Ambulatory Surgical Center (ASC). The proposed rule was finalized and announced on November 1, 2022, and rates will be effective January 1, 2023.

Key Points: 
  • The proposed rule was finalized and announced on November 1, 2022, and rates will be effective January 1, 2023.
  • The final CMS CY2023 Outpatient Prospective Payment System (OPPS) Rule increases payment rates for code C9769 covering the iTind procedure in HOPD and ASC facilities.
  • The rule changes are as follows:
    "We applaud CMS for recognizing the value of the iTind procedure.
  • Clinical evidence demonstrates that the iTind procedure safely and effectively relieves symptoms while preserving sexual function.

Global Endometrial Ablation Devices Market Analysis Report 2022: A $990.9 Million Market in 2021 - Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 1, 2022

The Global Endometrial Ablation Devices Market was valued at USD 990.9 Million in the year 2021 with the Americas region leading the regional market share.

Key Points: 
  • The Global Endometrial Ablation Devices Market was valued at USD 990.9 Million in the year 2021 with the Americas region leading the regional market share.
  • The Asia Pacific Endometrial Ablation Devices market is predicted to be the hotspot and the most lucrative region for market participants worldwide.
  • The report analyses the Endometrial Ablation Devices Market by Device Type (Radiofrequency Ablators, Thermal balloon Ablators, Cryoablation Devices, Hydrothermal Ablators, Electrical Ablators and Others).
  • The Global Endometrial Ablation Devices Market has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).

Rising Safety Regulations to push Non-Destructive Testing Equipment Market Grow at a Positive 6.2% CAGR & Attain Stupendous Revenue During the Forecast Period of 2022-32 - Future Market Insights, Inc.

Retrieved on: 
Tuesday, November 1, 2022

NEWARK, Del., Nov. 1, 2022 /PRNewswire/ -- The global non-destructive testing equipment market is anticipated to reach a valuation of US$ 31574.6 Mn in 2032, with demand growing at a positive CAGR of 6.2% from 2022 to 2032. Driven by an upsurge in safety regulations for the safe and reliable performance of machines and for quality control purposes, the target market will likely reach an estimated US$ 17324 Mn by the end of 2022. As non-destructive testing equipment is used to evaluate and inspect various aspects of materials, components, and assemblies, the market for this equipment is expected to observe a heightened demand during the forecast period.

Key Points: 
  • With a growing emphasis on enhancing the quality and durability of various materials, the demand for non-destructive testing equipment is also anticipated to grow in the international market.
  • The use of non-destructive testing equipment has been shown to ultimately lessen maintenance and repair costs, thus, driving the demand for the non-destructive testing equipment market during the forecast period.
  • The non-destructive testing equipment market in North America will hold about 28.5% of the global market share in 2022.
  • Besides, Europe too will demonstrate notable growth by accounting for 23.8% of the global non-destructive testing equipment market shares.